UPDATE: Sio Gene Therapies warns of ‘significant’ layoffs after ditching final two assetsnews2022-04-28T14:21:04+00:00April 28th, 2022|FierceBiotech|
UPDATE: Sio Gene Therapies warns of ‘significant’ layoffs after ditching final 2 assetsnews2022-04-28T14:21:04+00:00April 28th, 2022|FierceBiotech|
Pfizer’s phase 3 DMD gene therapy test resumes after FDA hold, but decision on advanced patients still pendingnews2022-04-28T12:55:20+00:00April 28th, 2022|FierceBiotech|
SURMOUNT-able: Lilly’s tirzepatide clears high bar set by Novo’s Wegovy in obesitynews2022-04-28T09:31:09+00:00April 28th, 2022|FierceBiotech|
GV, Sanofi drive British biotech OMass to $100M series B, fueling work on undruggable targetsnews2022-04-28T05:33:53+00:00April 28th, 2022|FierceBiotech|
Lipids that wind down inflammation could be a critical therapeutic tool for MSnews2022-04-27T23:05:10+00:00April 27th, 2022|FierceBiotech|
After Amgen deal, Plexium maintains momentum with AbbVie neurological partnershipnews2022-04-27T20:47:41+00:00April 27th, 2022|FierceBiotech|
Future shaky at Solid Bio as it shaves off 35% of workforce, chief operating officer plans exitnews2022-04-27T14:47:37+00:00April 27th, 2022|FierceBiotech|
BridgeBio strategy head departs amid company’s second round of layoffs this yearnews2022-04-27T14:39:59+00:00April 27th, 2022|FierceBiotech|
BridgeBio strategy head departs amid company’s 2nd round of layoffs this yearnews2022-04-27T14:39:59+00:00April 27th, 2022|FierceBiotech|
